Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha^® (evolucumab). This follows landmark results demonstrating Repatha significantly reduced the risk of major adverse cardiovascular events (MACE) in individuals without a prior history of heart attack or stroke in the VESALIUS-CV Phase 3 trial.

In support of the Trump Administration's efforts to lower drug prices for Americans, Repatha will be available through AmgenNow at a monthly price of $239, nearly 60% lower than the current U.S. list price. The program is open to all patients, including those who are uninsured or in high-deductible health plans or prefer to pay with cash or out of pocket. The new direct-to-patient price is the lowest among the economically developed (G-7) countries and is being offered exclusively for the first time to U.S. patients.  

"Amgen is committed to finding new ways to help patients benefit from our medicines," said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen. "Repatha has already helped more than 5 million patients¹, and the AmgenNow program will make it easier for uninsured patients or those who choose to pay out-of-pocket to access treatment. This will allow even more Americans at increased risk of major adverse cardiovascular events to benefit from this effective medicine." 

Beginning today, AmgenNow will be available to all Repatha patients, including those who participate in government programs such as Medicare and Medicaid. Patients who use this program are not subject to insurer requirements for step therapy or prior authorization. The company also plans to make AmgenNow accessible via the TrumpRx website.

For more information, visit amgensupportplus.com/patient/repatha.